Introduction
The American physicist Richard Feynman was accredited with the assertion, ''What I cannot create, I do not understand.'' When translated into the context of neurological disease, Feynman's statement could be considered an explicit challenge. If sufficient progress has been made toward deciphering the genetic and cellular basis of neural degeneration, then it should be possible to take the resulting knowledge and apply it to the development of accurate models for neurological disease. To date, such efforts have been met with greatest success in animal models for diseases of the nervous system. Unquestionably, modeling of neurological diseases in genetically manipulated animals has led to important advances in the understanding of pathogenic mechanisms, in particular those relevant to neurodevelopmental and neurodegenerative disorders. These animal models, particularly rodent models, have become ''workhorses'' for both mechanistic studies and drug discovery. While the continued importance of animals in translational research is indisputable, genetic and anatomical variation between rodents and man have led to imperfect phenotypic correlations among genetic models and the human diseases they attempt to recapitulate. Furthermore, most neurodegenerative diseases are sporadic in etiology, arising from what appear to be the complex interactions of genetic and environmental risk factors. As a result, it may be difficult or impossible to fully model these conditions in animals. But perhaps most notably, preclinical successes in the treatment of existing animal models have not translated well into clinical benefits for patients. Thus there must be aspects of neurological disease that we do not understand well enough to recapitulate.
It is possible that an improved understanding of many neurological diseases could be developed if there were accurate cellular models of these conditions that relied only on actual patient genotypes and resulted in degeneration of the disease affected human neural types in vitro. If such cellular models of neural degeneration could be reconstituted and studied in concert with existing animal models, it is possible that improved outcomes for patients might eventually result. However, to date, attempts to develop in vitro models for nervous system degeneration have been stymied by the fundamental inaccessibility of many specific human neural subtypes.
While peripheral nerves or muscle are sometimes clinically accessed for pathological studies, routine sampling of tissue from the brain and spinal cord of living patients are usually only performed in rare conditions where a tissue diagnosis is necessary for subsequent clinical management. Thus most neural cell types cannot be accessed in any quantity from living patients. Although postmortem samples from the nervous system can be obtained, such tissue is ravaged by end-stage manifestations of disease. While neuropathological samples can be helpful at times in making a specific diagnosis, they have not always proven useful for revealing how the neurological disease process unfolds over time. Even if the routine sampling of neurons directly from patients were possible, an inability to expand and study these postmitotic cells in vitro for prolonged periods would further diminish their utility.
However, recent advances in the areas of stem cell and reprogramming biology now seem to provide a novel route to the generation of a wide variety of neural types for studying neurological disease. New ''stem cell'' models of disease provide an emerging and exciting opportunity to test Feynman's assertion of whether or not we ''understand'' enough concerning the underlying causes of neurological disease to accurately ''create'' neurodegenerative processes in vitro. Here we review emerging efforts to use stem cell and reprogramming approaches to produce specific human neural subtypes carrying patient genotypes as well as initial attempts to monitor these neurons for hallmarks of disease-specific degenerative processes.
As we will describe, when stem cells are combined with methods that direct their differentiation along the lineages leading to the neuronal types principally affected in a given neurological disease, this new resource now provides exciting opportunities for disease modeling, drug discovery, predictive toxicology, and transplantation therapy (Figure 1 ). The implicit promise of this technology is that patient-derived iPS cells may offer unprecedented opportunities to study the developmental progression of a neurological disease process in vitro. While the full potential of this approach is only beginning to be realized, initial attempts to use it for the modeling of several neurological disorders have provided the proof of principle that further insight into more complex disorders may be possible.
Toolkit for Neurological Disease Modeling using iPS Cells Generation of Patient-Specific iPS Cells
Human pluripotent stem cells are characterized by the ability to renew indefinitely in culture while retaining their capacity to differentiate into most, if not all, cell types (Yu and Thomson, 2008) . This differentiation potential includes the ability to produce previously inaccessible cell types from the nervous system, which has obvious implications for the study and treatment of neurological disease. Human embryonic stem (hES) cells are pluripotent stem cells derived from the inner cell mass of the blastocyst-stage embryo. These preimplantation embryos generally exist in excess of clinical need at in vitro fertilization (IVF) clinics and are donated to research by individuals under informed consent Cowan et al., 2004; Thomson et al., 1998) . Of particular interest for the study of neurological disease are stem cell lines produced from embryos discarded after preimplantation genetic diagnosis (PGD) because they were identified to carry disease-associated mutations. Such stem cell lines would in turn be expected to carry the disease genes responsible for the condition and could prove useful for mechanistic studies. To date, a very small number of hES cell lines harboring known mutations for a few monogenic neurological disorders have been established (Eiges et al., 2007; Mateizel et al., 2006 Mateizel et al., , 2010 . This scarcity of PGD stem cell lines is partly due to the small number of embryos 
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Disease and patient-specific pluripotent stem cells can be derived from several sources. (A) Embryonic stem (ES) cells can be derived from donated embryos identified to carry a disease-causing genetic mutation discovered through preimplantation genetic diagnosis (PGD). However, ES cells from diseased PGD embryos are a scarce resource and lack correlative information of disease onset and progression. (B) Pluripotent stem cells can also be derived through defined factor reprogramming of readily obtainable somatic cells from patients with a neurological disease, with or without known genetic mutations. Typically, skin fibroblasts obtained from patients are the donor somatic cell type used for reprogramming, though virtually any cell type can be used. (C) Pluripotent stem cells are expanded in culture and directed to differentiate into cell types important for a particular disease. (D) Neurons and other neural cell types are studied over time in vitro and, depending on the disease process of interest, can be evaluated for defects in neurogenesis, migration, morphology, synaptic connectivity, survival, and electrophysiological function. Aberrant protein aggregation and non-cell-autonomous factors can also be tested. (E) Once disease-relevant cellular phenotypes are identified, rescue experiments can be performed to help validate the disease model and assays developed for drug discovery. Neural cells and other clinically important cell types such as cardiomyocytes and hepatocytes obtained through these methods may also be used for studies on predictive toxicology (further discussed in text). (Urbach et al., 2004) . Unfortunately, disease-specific PGD embryos, as a resource, are limited in number and producing disease-specific ES cell lines by homologous recombination is highly inefficient. In addition, in both cases, these approaches do not allow for the modeling of sporadic disease or for correlations to be made between in vitro cellular phenotypes and clinical observations made over the lifetime of the patient. Another approach for using hES cell lines for disease modeling is to genetically modify them to express a disease-causing transgene using cell-type-specific promoters (Karumbayaram et al., 2009a) . However, this approach would again only be useful for modeling monogenic diseases caused by highly penetrant mutations and not for modeling complex disorders for which genetic determinants are either unknown or poorly understood. In contrast, the ''reprogramming'' of somatic cells allows the production of induced pluripotent stem (iPS) cells, which possess all of the salient characteristics of ES cells. These iPS cells can be generated using readily accessible tissue from patients with any condition. The obvious advantage of such an approach is that patient-specific iPS cells carry the precise genetic variants, both known and unknown, that contributed to disease, residing in the context of the patient's own genetic background. Thus, any cellular phenotypes observed could be correlated with clinical benchmarks such as rate of disease progression. Additionally, patient-specific iPS cells may eventually serve as a customizable resource for personalized regenerative medicine, drug testing, and predictive toxicology studies. Since the initial derivations of patient-specific iPS cell lines (Dimos et al., 2008; Park et al., 2008a) , there has been a dramatic expansion in the number of diseases for which cell lines have now been created (Table 1) .
The approach of induced pluripotency by defined factors has emerged as an alternative method for the derivation of human pluripotent stem cells that overcomes many of the limitations associated with the derivation and manipulation of hES cells. In 2006, Shinya Yamanaka's group demonstrated that the combined ectopic expression of the transcription factors Oct4, Sox2, Klf4, and c-Myc was sufficient to reprogram mouse fibroblasts into what were termed induced pluripotent stem cells, or simply iPS cells (Takahashi and Yamanaka, 2006) . Shortly thereafter this approach was recapitulated using human fibroblasts, resulting in the generation of human iPS cells (Lowry et al., 2008; Park et al., 2008b; Takahashi et al., 2007; Yu et al., 2007) . Subsequent studies have now demonstrated that iPS cells can be generated, albeit with lower efficiency, using only three factors (OCT4, SOX2, and KLF4) (Nakagawa et al., 2008) .
Human iPS cells have very similar properties to hES cells. These include similarities in their morphology, proliferation rate, gene expression profiles, and capacity to differentiate into various cell types of the three embryonic germ layers in vitro. This differentiation potential can be manifested through a variety of methods. These include in vitro approaches such as differentiation in cell aggregates called embryoid bodies (EBs), and in vivo strategies, including the formation of teratomas, which are benign tumors formed after injection of the stem cells into immunodeficient mice (Lowry et al., 2008; Park et al., 2008b; Takahashi et al., 2007; Yu et al., 2007) .
Induced pluripotency by defined factors has made possible the generation of patient-specific iPS cells (Table 1) . Because of the relative ease with which iPS cells can be generated from accessible human tissue, such as fibroblasts from a skin biopsy, the derivation of iPS cell lines from patients suffering from a variety of diseases has become increasingly routine. Many iPS cell lines have now been produced for a variety of neurological diseases including amyotrophic lateral sclerosis (ALS) Dimos et al., 2008 ), Huntington's disease (HD) (Park et al., 2008a) , spinal muscular atrophy (SMA) (Ebert (Nguyen et al., 2011; Park et al., 2008a; Seibler et al., 2011; Soldner et al., 2009) , familial dysautonomia , and Rett syndrome (Cheung et al., 2011; Marchetto et al., 2010) . Because of their defining pluripotency property, these iPS cells can be differentiated in vitro into any desired cell type, including those specifically affected in a particular neurological disorder, such as spinal motor neurons for the study of SMA and ALS Dimos et al., 2008; Ebert et al., 2009) . Thus far, the majority of reported iPS cell lines have been generated using viral transduction of vectors that encode reprogramming transcription factors. This approach results in multiple genomic integrations of the viral transgenes. While the potential for mutagenesis and tumorigenicity that result from these insertions may preclude the use of ''first-generation'' iPS cell lines for transplantation medicine (Okita et al., 2007) , early proof-of-principle studies indicate that they are probably adequate for disease-modeling purposes (Ebert et al., 2009; Lee et al., 2009; Marchetto et al., 2010) .
However, newer strategies for reprogramming are rapidly emerging and some of these allow for the derivation of genetically unmodified human iPS cells (reviewed in Gonzá lez et al., 2011) . These novel reprogramming approaches include the use of nonintegrating RNA viruses (Fusaki et al., 2009) or episomal vectors , the delivery of excisable lentiviral or transposon vectors (Kaji et al., 2009; Soldner et al., 2009) , the transduction of the reprogramming proteins modified for cellular uptake (Kim et al., 2009) , and the direct delivery of synthetic mRNAs modified to escape the endogenous antiviral cell response (Warren et al., 2010) . In addition, small molecules can be used to increase the reprogramming efficiency or to replace the activity of one or more of the reprogramming factors (Huangfu et al., 2008; Lin et al., 2009; Zhu et al., 2010) . However, the generation of iPS cells by using only small molecules has yet to be reported. Thus, the ultimate method in deriving disease-specific iPS cell lines will depend on their downstream use.
As a cautionary note, it is important to mention that there have been reports indicating differential gene expression and DNA methylation patterns in hES cells and hiPS cells (Chin et al., 2009; Doi et al., 2009; Lister et al., 2011) . However, it is not yet clear what the consequences of this variation are upon stem cell differentiation or functionality of the resulting cell types, if any. From a neurological disease-modeling point of view, it might be more relevant to determine whether hES cells and hiPS cells differ in their ability to reliably generate the differentiated neural cell type(s) of interest. Two recent studies, including one from our group, compared human ES and hiPS cell lines in terms of their capacity to generate functional motor neurons Hu et al., 2010) . While both studies found variable differentiation efficiency among individual iPS cell lines, Hu and colleagues reported that iPS cell differentiation capacity toward motor neurons was significantly reduced compared to that of hES cells (Hu et al., 2010) , whereas our group found a similar range of differentiation efficiencies when a much larger number of hES and hiPS cell lines were analyzed . Our experience suggests that each pluripotent stem cell line, regardless of whether it is an iPS cell or hES cell line, has its own discrete properties that must be taken into consideration when using it for directed differentiation in disease-modeling studies. Recently, a genomics-based assay has been developed to rapidly characterize the differentiation potential of pluripotent stem cell lines that may aid in predicting the best lines to move forward for neurological applications (Bock et al., 2011) . Furthermore, analyses of chromosomal aberrations (Mayshar et al., 2010) , subchromosomal copy-number variation (Hussein et al., 2011; Laurent et al., 2011) , protein-coding point mutations (Gore et al., 2011) , and DNA methylation profiles (Lister et al., 2011) indicate that hiPS cells can exhibit genetic and epigenetic abnormalities, which can result from the reprogramming process itself or, as with hES cells (Baker et al., 2007) , from their adaptation to long-term in vitro culture. While the functional implications of these alterations remain to be elucidated, in the context of disease modeling they underscore the importance of using more than one iPS cell line per patient and control, as well as multiple disease and control genotypes. This would minimize the possibility that phenotypic differences resulting from genomic or epigenetic instability in iPS cells are incorrectly presumed to be relevant to the disease model.
Differentiation of Human Pluripotent Stem Cells into Disease-Relevant Neural Cell Types
A critical component of neurological disease modeling using human pluripotent stem cells is the availability of reliable protocols that can efficiently direct stem cell differentiation into the specific neural cell types affected in disorders of interest ( Figure 2 ). Insights into inductive pathways that drive neural differentiation have been gained from early studies of mouse, chick, and Xenopus embryos. Knowledge of these pathways has informed rational approaches now routinely used to direct the differentiation of pluripotent stem cells in vitro (reviewed in Gaspard and Vanderhaeghen, 2010; Murry and Keller, 2008; Peljto and Wichterle, 2011; Schwartz et al., 2008) . The first step in most protocols is the differentiation of the pluripotent stem cells into a population of neural progenitors. This initial ''neural induction'' step can be accomplished by using spontaneous differentiation, stromal feeder coculture, treatment with retinoic acid, or culture in defined media containing the mitogens FGF2 and EGF2 (Joannides et al., 2007; Murry and Keller, 2008) . More efficient neural induction of human ES and iPS cells can be achieved by dual inhibition of Activin/Nodal/TGF-b and BMP signaling using recombinant endogenous inhibitors or smallmolecule antagonists Smith et al., 2008; Zhou et al., 2010 ). These neural progenitors can then be patterned along the rostro-caudal and dorso-ventral axes using specific morphogens and growth factors ( Figure 2 ).
Much as in the embryo, it appears that a variety of neural phenotypes can be obtained, depending on the combination and timing of the inductive signals to which progenitors are exposed. Disease-relevant neural cell types that have been generated in vitro by directed differentiation of human pluripotent stem cells include spinal motor neurons Dimos et al., 2008; Lee et al., 2007b; Li et al., 2005) , midbrain dopaminergic neurons Cho et al., 2008; Hargus et al., 2010; Nguyen et al., 2011; Roy et al., 2006) , basal forebrain cholinergic neurons (Bissonnette et al., 2011) , cortical progenitors (Eiraku et al., 2008) , and oligodendrocytes Kang et al., 2007; Keirstead et al., 2005; Nistor et al., 2005) . In addition, neural crest cell derivatives including sensory neurons and Schwann cells can also be generated .
One of the first directed differentiation methods to be developed is that for the production of spinal motor neurons. Using two developmentally relevant morphogens, retinoic acid (RA) and Sonic hedgehog (Shh), Wichterle and colleagues showed that mouse ES cells could be directed to differentiate into functional spinal motor neurons (Wichterle et al., 2002) . RA induces neuralization and caudalization of stem cells, while the ventralizing activity of Shh converts spinal progenitor cells to motor neurons (Peljto and Wichterle, 2011; Wichterle et al., 2002) . RA treatment and induction of SHH signaling have also been used to derive functional spinal motor neurons from human pluripotent stems cells Dimos et al., 2008; Karumbayaram et al., 2009b; Lee et al., 2007b; Li et al., 2005) . Lee and colleagues demonstrated the in vivo potential of hES cell-derived spinal motor neurons using transplantation assays into the spinal cord of developing chick embryos and of adult rats (Lee et al., 2007b) . Both approaches yielded robust engraftment and maintenance of motor neuron phenotype and, when transplanted in developing chick spinal cord, were capable of forming long axonal projections to skeletal muscle (Lee et al., 2007b) .
Beyond its caudalizing role on neural progenitors, RA signaling also affects spinal motor neuron subtype specification by imposing a rostral cervical identity (Peljto and Wichterle, 2011; Wichterle et al., 2002) . Using inhibition of Activin/Nodal signaling for neural induction, functional human spinal motor neurons could also be specified in a retinoid-independent pathway, which results in the production of more posterior motor neuron types (Patani et al., 2011) . As disorders like ALS selectively target certain subtypes and pools of motor neurons (Kanning et al., 2010) , the ability to direct the differentiation of stem cells into specific motor neuron subtypes could have important implications for disease modeling and studies aiming to understand mechanisms of selective vulnerability.
Another clinically relevant neuronal subtype that has been generated in vitro from human pluripotent stem cells is midbrain dopaminergic (DA) neurons, which are preferentially affected in PD. Several studies on the controlled differentiation of hES and hiPS cells into populations of neurons expressing tyrosine hydroxylase have been reported (Ben-Hur et al., 2004; Chambers et al., 2009; Cho et al., 2008; Cooper et al., 2010; Hargus et al., 2010; Perrier et al., 2004; Roy et al., 2006; Soldner et al., 2009; Yan et al., 2005) . Most of these differentiation strategies rely on the patterning of neural progenitors by the combined activity of SHH and FGF8, first shown to have a significant effect on dopaminergic differentiation by seminal work of Lee and colleagues using mouse ES cells (Lee et al., 2000) . Methodological improvements to enhance human dopaminergic differentiation in vitro include coculture with immortalized human fetal astrocytes (Roy et al., 2006) , derivation and expansion of Various methods of neural induction of pluripotent stem cells have been described such as embryoid body formation, retinoic acid treatment, stromal feeder cocultures, or defined media containing mitogens FGF2 and EGF. Inhibition of TGFb signaling using various molecules enhances neuralization. Defined combinations of morphogens, small molecules, growth factors, or transcription factors have been shown to specify neural progenitors to certain subtypes of neurons as well as glial cells. Some of the best-characterized pathways of clinically important cell types are illustrated above and described in the main text. Efficient methods to produce astrocytes have yet to be determined.
homogenous ''spherical neural masses'' from neural precursors (Cho et al., 2008) , and dual inhibition of BMP/TGF-b signaling during neural induction . The in vivo functionality of human DA neurons derived from hES cells (Ben-Hur et al., 2004; Cho et al., 2008; Roy et al., 2006) and hiPS cells has been demonstrated by transplantation assays into the striatum of 6-hydroxydopamine-lesioned parkinsonian rats showing partial recovery of motor function. A recent study reported the controlled differentiation of hES cells to basal forebrain cholinergic neurons (BFCN), the neuronal subtype preferentially affected in Alzheimer's disease (AD) and associated with cognitive decline (Bissonnette et al., 2011; Mesulam et al., 2004) . Bissonnette and colleagues devised two strategies for the generation of a predominantly pure population of BFCN from hES cell-derived neural progenitors. While one method relied on the use of the diffusible ligand BMP9, the other strategy involved the transgenic overexpression of two developmentally relevant transcription factors, Lhx8 and Gbx1, which were further shown to act downstream of BMP9 signaling (Bissonnette et al., 2011) . hES cell-derived BFCNs were shown to stably engraft into murine hippocampal slice cultures and to generate electrophysiologically functional cholinergic synapses (Bissonnette et al., 2011) .
In addition to various neuronal subtypes, neural progenitors obtained from human pluripotent stem cells are also capable of giving rise to glial cell types of the CNS, astrocytes and oligodendrocytes (Zhang et al., 2001) . When neural differentiation cultures are maintained for several weeks, cells with molecular characteristics of astrocytes (GFAP+ and S100b+ cells) can be detected (Johnson et al., 2007; Zhang et al., 2001 ). However, directed differentiation protocols and functional characterization of astrocytes derived from human ES or iPS cells have yet to be reported. In contrast, there are already a number approaches for the efficient directed differentiation of human oligodendrocytes and their progenitors from hES cells (Hatch et al., 2009; Kang et al., 2007; Keirstead et al., 2005; Nistor et al., 2005) . The ability of these differentiated cells to myelinate axons has been demonstrated both in vitro by coculture with rat hippocampal neurons (Kang et al., 2007) and in vivo by transplantation into the shiverer mouse model of dysmyelination (Nistor et al., 2005) . Furthermore, preclinical studies evaluating hES cell-derived oligodendrocyte progenitor cell (OPC) transplants into adult rats have reported improvement of locomotor recovery in both thoracic and cervical spinal cord injury (SCI) models (Keirstead et al., 2005; Sharp et al., 2010) . These studies have been translated into the first clinical trial using hES cell-based therapy, which was initiated by Geron Corporation and currently a phase I safety study of hES cell-derived OPCs administered to patients with neurologically complete, subacute SCI (http:// clinicaltrials.gov/).
Neural progenitors generated in vitro can also be directed toward cell types of the peripheral nervous system. Lee and colleagues demonstrated that human ES cells could be used to derive neural crest (NC) precursors that in turn could be directed to differentiate into peripheral neurons and Schwann cells, among other NC derivatives (Lee et al., 2007a) . NC precursors derived from hES cells were also able to survive and differentiate in vivo upon transplantation into developing chick embryos and adult immunodeficient mice (Lee et al., 2007a) . More recently, protocols for the prospective purification and propagation of NC cells derived from both hES and hiPS cells have also been reported .
Case Studies in iPS Cell Neurological Disease Models
Although a good deal of progress continues to be made in developing a toolkit for generating iPS cells and directing their differentiation along specific lineages, early studies of neurons made from iPS cells have begun to move forward. Thus far, only a few hiPS cell models of neurological diseases have yielded convincing phenotypes. Among these models, disease-related deficits in cell survival, neuronal morphology, neuronal migration, synapse formation, and electrophysiological function have been described. These examples, described below, have provided the initial ''proof of concept'' that disease modeling is possible from disease-specific iPS cells (Figure 3 ).
Spinal Muscular Atrophy
The first example of using patient-derived iPS cells to model any human disease was for the study of spinal muscular atrophy (SMA) (Ebert et al., 2009) . SMA is an autosomal-recessive disease characterized by the selective degeneration of lower motor neurons in the brainstem and spinal cord, which in turn leads to progressive muscle atrophy and weakness. SMA is the leading genetic cause of infant mortality. Clinically, SMA is classified into distinct subgroups (I-IV) based on several clinical characteristics including age of onset, ability to attain motor milestones such as sitting or independent walking, and time to death (Lunn and Wang, 2008) . Type I, the most common form of the disease, generally sets in before 6 months of life. Infants have severe muscle weakness, difficulty with sucking and swallowing, tongue fasciculations, and intercostal muscle weakness leading to profound respiratory difficulties. These children never acquire the ability to sit up independently and usually die within their first 2 years of life.
The vast majority of SMA cases are caused by homozygous mutations, most often a deletion of Survival of Motor Neuron-1 (SMN1). SMN is thought to be a general housekeeping gene involved in the biogenesis of small nuclear ribonucleoproteins important for pre-mRNA splicing, but might also have a specific role in RNA transport in neurons (Burghes and Beattie, 2009 ). However, precisely how a deficiency in SMN, a ubiquitously expressed protein, produces specific degeneration of lower motor neurons remains unclear (Monani, 2005) . In humans, a highly homologous gene, SMN2, which lies centromeric to SMN1 on chromosome 5q, partially but poorly compensates for reduced SMN levels. While five nucleotides, none of which lead to an amino acid change, differentiate SMN2 from SMN1, SMN2 mRNA, through alternative splicing, results predominantly in transcripts lacking exon 7, thereby leading to a truncated, unstable protein (Lorson et al., 2010) . Only 10% of the transcripts are translated into functional full-length SMN protein.
As a result, SMN2 normally contributes little to the overall levels of full-length SMN protein. However, copy numbers of the SMN2 gene in the human genome are variable, ranging from 0 to 4 copies in the genome. Higher SMN2 copy numbers result in increased full-length protein levels, which correlate with milder phenotypes in patients (Mailman et al., 2002) . As such, current targets for therapy have focused on drugs that either promote overall SMN2 expression or promote exon 7 inclusion (Sendtner, 2010) . While transgenic mouse models exist, mice lack SMN2 and homozygous knockout of SMN1 leads to embryonic lethality, which has necessitated generating transgenic mice that harbor human SMN2 (Hsieh-Li et al., 2000; Monani et al., 2000) .
To create a patient-specific iPS cell model of SMA, skin fibroblasts were obtained from a child with SMA type 1. The subject was 3 years old at the time of sample collection and had two copies of SMN2. Fibroblasts from his unaffected mother were also reprogrammed to iPS cells by lentiviral transduction of OCT4, SOX2, NANOG, and LIN28 (Ebert et al., 2009) . One iPS clone from the SMA child (iPS-SMA) and the unaffected mother (WT-iPS) was subsequently used in their studies. As expected, SMA fibroblasts and iPS cells lacked SMN1 expression, expressed the alternatively spliced delta exon 7 mRNA, and demonstrated reduced levels of full-length SMN contributed by SMN2 expression. Following directed differentiation of iPS cells to spinal motor neurons, no significant differences in motor neuron numbers were seen after a total of 4 weeks of in vitro differentiation. At 6 weeks, the total numbers of neurons, based on the overall number of cells positive for neuronal marker TUJ1, were equivalent between WT and SMA (15.78% in WT and 15.55% in SMA). However, when cultures were specifically evaluated for motor neurons based on coexpression of TUJ1 and ChAT, motor neuron numbers were reduced from the SMA cultures (4.3% in SMA versus 24.2% in WT). In addition, SMAiPS motor neurons were smaller in soma size and synapse formation appeared to be compromised (Ebert et al., 2009 ).
To demonstrate that SMN production could pharmacologically be altered in this disease line, two drugs known to increase SMN production were tested. SMN can be localized to discrete, punctuate structures called ''gems'' (Liu and Dreyfuss, 1996) . SMA fibroblasts and iPS cells lacked nuclear SMN gems whereas gems were detected in WT cells (Ebert et al., 2009 ). Treatment with tobramycin or valproic acid, which are know to increase full-length SMN mRNA by upregulating the SMN2 promoter and activating splicing factors that produce transcripts containing exon 7 (Brichta et al., 2003; Sumner et al., 2003) , led to increased nuclear gem formation and a 2-to 3-fold increase in SMN protein expression in SMA-iPS cells (Ebert et al., 2009) .
Demonstrating that increased SMN production can occur in motor neurons derived from SMA-iPS cells and whether this leads to rescue of the morphological and motor neuronal specific survival phenotype shown in this model would clearly be important next steps. In addition, similar analysis from additional lines and patient samples and healthy controls will help clarify the reproducibility of these phenotypes. It would also be informative to determine whether variable copy numbers of SMN2, known to modify the disease severity in patients and phenotypes in mice models, modify the severity of the iPS-derived motor neuron phenotypes and would be additional validating steps for this model. While numerous compounds have been identified in drug screens that assay for increased SMN production in easily accessible cell types, motor neurons derived from SMA iPS cells will provide for relevant assays that could assess potential phenotypic benefit in motor neuron survival, axonal outgrowth, and neuromuscular junction numbers. Such an approach would be more relevant than pharmacological screening using human (Marchetto et al., 2010) . In red are disease phenotypes described in these iPS cell models. In blue are responses to specific drug treatments. See text for detailed discussions of each of these models.
nonneuronal cells such as patient fibroblasts and lymphoblastoid cell lines (Chang et al., 2001; Sumner et al., 2003) . Thus, it could provide an additional assay to select the most promising compounds to take forward in SMA clinical trials. Familial Dysautonomia Familial Dysautonomia (FD, MIM 223900), also known as Hereditary Sensory and Autonomic Neuropathy, Type III (HSAN III) or Riley-Day Syndrome, is a rare autosomal-recessive disorder caused by mutations in the I-kB kinase associated protein (IKB-KAP) gene. FD is primarily a disorder of peripheral sensory and autonomic neurons, although central neuronal dysfunction is probably also involved. FD patients have alterations in pain and temperature sensitivity, absent deep tendon reflexes, autonomic crises (hypertension, tachycardia, hyperhydrosis), postural hypotension, GI dysmotility, and cardiovascular and respiratory disease (Axelrod, 2004) . While the constellation of symptoms can be variable from patient to patient, the clinical diagnosis is based on several cardinal findings such as the absence of overflow tears, lingual fungiform papillae, depressed or absent patellar reflexes, and lack of an axonal flare after intradermal histamine. Patient are almost exclusively of Ashkenazi Jewish anscestory. Most FD patients do not survive beyond 40 years of age. Pathologically, FD is characterized by reduction in unmyelinated and small myelinated peripheral axons, loss of neurons in the dorsal root ganglia, loss of autonomic neurons in the superior cervical sympathetic ganglia, the parasympathetic sphenopalatine ganglia, and the intermediolateral gray columns of the spinal cord. While the exact function of the IKAP protein is not clearly understood in this case, it has been proposed to serve as a scaffold protein involved in assembling the holo-Elongator complex. This complex is in turn involved in RNA polymerase II-mediated transcription elongation and transcriptional regulation of genes, some of which are important in actin cytoskeletal regulation and cell motility and migration (Naumanen et al., 2008) . The causative mutation in over 98% of patients is a T / C transition in a donor splice site of intron 20 leading to variable tissue-specific skipping of exon 20 (IVS20 + 6T/ C), causing a frameshift and introduction of a premature stop codon (Slaugenhaupt et al., 2001) . The mutant transcript is produced in abundant amounts in central and peripheral neural tissues from patients leading to reduced levels of functional IKAP protein in a tissue-specific manner. The efficiency of generating the normal, wild-type full length IKBKAP transcript is especially reduced in sensory and autonomic neurons and may account for the selective degeneration of these neurons in patients (Cuajungco et al., 2003) .
Using lentiviral transduction of patient-derived fibroblasts with SOX2, KLF-4, OCT-4, and c-MYC, iPS cell lines from three patients with FD and unaffected controls were established ). To evaluate tissue-specific differences in IKBKAP mRNA expression, iPS cell lines were directed to differentiate along central and peripheral nervous systems and hematopoietic, endothelial, and endodermal precursor lineages. Using cell surface markers, each population of lineage-specific cells was then isolated. Normal IKBKAP expression was found to be especially reduced in FD-iPS-derived neural crest precursor cells, consistent with a tissue-specific effect. Comparative transcriptome analysis of FD-iPS cells versus control lines revealed 35 transcripts that were significantly increased and another 54 transcripts that were significantly decreased in disease-specific cells. Interestingly, the authors reported decreased levels of transcripts with putative roles in peripheral neurogenesis and neuronal differentiation. It was also observed that in spontaneously differentiating cultures of neural precursor cells, reduced numbers of TUJ1-positive cells were seen in the FD cultures suggesting a defect in neuronal differentiation. Functional deficits were also seen. FD neural precursors exhibited a decreased in migratory behavior in a wound healing in vitro assay and this defect correlated with a reduction in paxillin positive focal adhesions known to be important for cell spreading and migration .
To test whether phenotypes found in this FD-iPS cell model could be rescued with a candidate drug, the effect of kinetin, a naturally occurring dietary ingredient and plant hormone was evaluated. Kinetin had been previously identified from a National Institute of Neurological Disorders and Stroke compound library to increase wild-type IKBKAP expression in patient lymphoblastoid cell lines (Slaugenhaupt et al., 2004) . Furthermore, oral administration of kinetin to healthy heterozygous patients increases IKBKAP mRNA expression in lymphocytes (Gold-von Simson et al., 2009). Kinetin-treated FD-iPS-derived neural precursor cells resulted in markedly reduced levels of mutant IKBKAP splice variant and increased the level of normal IKBKAP . When added to neural precursor cells in culture, kinetin failed to ameliorate the defects in neurogenesis or migration ). However, when kinetin was continuously given to FD-iPS cells prior to differentiation, a significant increase in neuron number was seen but the migratory deficit persisted, suggesting a partial rescue of disease phenotypes. Nonetheless, the FD-iPS cell model will be a powerful model to test future therapies as several disease-relevant assays were described. Rett Syndrome Perhaps the most extensive description of disease-related phenotypes using patient-derived iPS cells is for Rett Syndrome (RTT, MIM 312750). RTT syndrome is a neurodevelopmental disorder in the family of autism-spectrum disorders. Classical RTT is clinically characterized by apparently normal early development, followed at 6-18 months by regression of developmental milestones, loss of purposeful hand skills, loss of acquired spoken language, gait abnormalities, and stereotypic hand movements (Neul et al., 2010) . RTT primarily affects girls and is caused by X-linked mutations in the gene encoding methylCpG binding protein (MeCP2) protein (Amir et al., 1999) . MeCP2 is thought to function as a transcriptional regulator, both during repression of transcription by interactions with methylated DNA and by recruitment of corepressors and activation of gene transcription (Adkins and Georgel, 2011) . In pathological tissues, the major findings are decreased brain size and neuronal size, reduced dendritic arborizations and spines, and defects in synaptogenesis (Armstrong, 2005; Shahbazian et al., 2002) . While neuronal-specific expression has been shown in several human and rodent studies, this view has been more recently challenged in that glial expression occurs, albeit at lower levels. It will be critical to resolve this issues as a non-cell-autonomous astrocytic involvement has been proposed (Ballas et al., 2009 ). iPS cells were generated using retroviral transduction of factors SOX2, OCT4, c-MYC, and KLF-4 from fibroblasts of four female RTT patients with distinct MeCP2 mutations along with non-affected patients (Marchetto et al., 2010) . On neural differentiation, no difference in neuronal survival was observed. However, examination of neurons in culture at 8 weeks after differentiation showed a reduced density of VGLUT1 puncta on glutamatergic neurons, suggesting a glutamate transport defect in the RTT neurons. Moreover, this phenotype could be recapitulated using shRNA knocking down MeCP2 in unaffected WTiPS cell-derived neurons whereas overexpression of MeCP2 in RTT-iPS and WT-iPS cell neurons increased VGLUT1 puncta, suggesting that MeCP2 may be involved in regulating glutamergic synapse number. Morphological characterization revealed reduced numbers of neuritic spines and smaller soma sizes on RTT neurons. Again, reduced spine density and soma size was also seen after knockdown with MeCP2 shRNA in WT neurons. Finally, RTT neuronal cultures showed a decrease in intracellular calcium oscillations and decreased frequency and amplitude of spontaneous postsynaptic currents as compared to WT neurons suggesting functional alterations at the neural network level (Marchetto et al., 2010) .
In this model, promising phenotypic rescue was also demonstrated pharmacologically. IGF-1 administration led to an increase in glutamatergic synapse number (Marchetto et al., 2010) . This is in agreement with the finding that systemic infusions of IGF-1 to MeCP2 knockout mice ameliorated several clinical symptoms and partially reversed reduced dendritic spine density and EPSC amplitudes (Tropea et al., 2009) . Second, use of the aminoglycoside gentamicin, which has activity in readingthrough of non-sense mutations, led to increased glutamatergic synapses in iPS cell-derived neurons from a patient with a Q244X nonsense mutation (Marchetto et al., 2010) . However, whether these pharmacological treatments led to rescue of dendritic spine density or the electrophysiological abnormalities described in this model was not shown.
Modeling of X-linked disorders has unique challenges from the perspective of X chromosome inactivation. Human female iPS cells, unlike mouse, appear to retain X chromosome inactivation upon cellular reprogramming, resulting in nonrandom, clonal populations of iPS lines with either the maternally or paternally inherited X chromosome inactivated (Tchieu et al., 2010) . From a disease-modeling perspective, this phenomenon could be utilized to identify iPS cell lines that express either the mutant or wild-type allele, thereby having an isogenic control. This was recently put to the test in a subsequent Rett iPS cell study. RTT-iPS cell lines were derived from a female patient with a functionally null mutation in MECP2 from a rearrangement resulting in deletions of exon 3 and 4 (D3-4) (Cheung et al., 2011) . Interestingly, the RTT-iPS cell lines in this study retained an inactive X chromosome in a nonrandom pattern consistent with other reports of human iPS cells from females (Tchieu et al., 2010) . By taking advantage of the nonrandom pattern of X chromosome inactivation in several RTT-iPS lines, an isogenic line where the X chromosome harboring the mutant allele had been inactivated, thereby resulting in cells expressing only the wild-type MECP2 allele, was identified (Cheung et al., 2011) . Upon neural differentiation, the pattern of X chromosome activation was maintained and lines expressing the mutant allele demonstrated smaller neuronal soma sizes as compared to the line expressing the wild-type allele (Cheung et al., 2011) . However, more detailed analysis of phenotypic differences was not described. Thus, iPS cell disease modeling of X chromosome-linked disorders in female lines could offer a unique advantage for modeling efforts. Friedrich's Ataxia Friedrich's Ataxia (FRDA, MIM 229300), an autosomal-recessive disorder, is the most common inherited ataxic disorder with an age of onset in the teenage years. Clinical characteristics include progressive ataxia of gait and limbs, dysarthria, muscle weakness, spasticity in the legs, scoliosis, bladder dysfunction, and loss of position and vibration sense. Cardiomyopathy and diabetes mellitus are systemic complications in some patients (Pandolfo, 2009 ). FRDA individuals have a GAA triple-repeat expansion in intron 1 of the Frataxin (FXN) gene of greater than 66 repeats whereas normal individuals may have between six and 34 . Pathological expansion of the GAA triplet leads to transcriptional silencing of FXN, resulting from heterochromatin formation, adoption of an abnormal DNA-RNA hybrid structure, or triplex DNA formation (Wells, 2008) . Length of GAA expansion correlates with Frataxin deficiency and disease severity and progression (Dü rr et al., 1996; Filla et al., 1996) . Frataxin is localized to the inner mitochondrial membrane where it is involved in biogenesis of iron-sulfur clusters and thus in the respiratory chain complex. Frataxin deficiency leads to mitochondrial dysfunction and increased oxidative damage (Pandolfo and Pastore, 2009 ). Iron accumulation is seen in affected tissues such as neurons and cardiomyocytes (Ye and Rouault, 2010) .
FRDA-iPS cell lines have been established from patients (Ku et al., 2010; Liu et al., 2010) . While a specific disease-related phenotype was not reported, the phenomenon of repeat-length instability that characterizes many of the repeat expansion disorders could be recapitulated in FRDA-iPS cells (Ku et al., 2010) . Analysis of global gene expression of FRDA-iPS lines (two clones from two patients) demonstrated that disease lines cluster with wild-type iPS and ES cell lines but with small differences (5%-7% global expression difference between FRDA-iPS lines and WT-iPS/ES lines). Interestingly, analysis of the most differentially expressed genes had known functions related to mitochondrial function, DNA repair, and DNA damage.
With regard to GAA repeat instability, iPS cells showed repeat expansions whereas parental fibroblasts did not (Ku et al., 2010) . Instability was specific to the abnormally expanded FXN as GAA expansions in WT FXN allele or at two unrelated loci with short GAA repeats remained unchanged. Repeat length changed over iPS cell passages in culture. To understand the mechanism of instability in this iPS cell system, analysis of differences in mRNA expression showed that MSH2, a critical component of the DNA mismatch repair (MMR) machinery important for mediating repeat-length instability, was highly expressed in FRDAiPS cells relative to donor fibroblasts. shRNA-mediated silencing of MSH2 resulted in shorter repeat lengths suggesting that FRDA iPS cells could be a useful system to evaluate the mechanisms of repeat expansions and contractions in disease.
It remains to be shown whether FRDA iPS cells will demonstrate cell-type-specific expansions of GAA repeats. GAA repeat (De Biase et al., 2007) . Given FRDA-iPS cells can be directed to differentiate into sensory neurons, as well as cardiomyocytes, the presence and mechanisms of tissue-specific expansion should be testable (Liu et al., 2010) .
Perspectives and Future Challenges
Genetic Modification of iPS Cells: Opportunities for Reporter Lines and Isogenic Controls? Disease modeling using human pluripotent stem cells might greatly benefit if the genome of these cells could be readily modified. For instance, the generation of transgenic ''reporter'' cell lines using fluorescent reporter genes under the control of celltype-specific promoters could enable the purification, tracking, and functional characterization of disease relevant cells after directed differentiation. It is our experience that use of such reporter genes is a significant consideration. Most in vitro differentiation strategies result in a heterogenous population of differentiated cells, which can include progenitors and a variety of cellular intermediates. Therefore, having the ability to prospectively identify, purify, and easily track the desired cell type by means of reporter-gene expression can facilitate downstream disease-specific assays, which could be hindered by the presence of other cell types.
The availability of stem cell lines harboring cell-type-specific reporters could also aid in the improvement of procotols for the directed differentiation of disease relevant cell types for which efficient differentiation techniques are not yet available. In addition, the ability to overexpress or downregulate a particular gene of interest could be used in the future to recapitulate or rescue a disease-relevant phenotype. For instance, loss-offunction monogenic disorders could be mimicked using a wildtype cell line by downregulation of the particular disease-associated locus. Conversely, a loss-of-function disease-specific phenotype could be rescued by overexpression of the wildtype form of the gene. Finally, the use of gene-targeting strategies to correct or induce a particular genetic defect will allow for the generation of isogenic lines with and without a disease genotype. This will be of particular relevance for disease modeling using patient-specific iPS cell lines, in which disease-specific phenotypes could be confounded by the variability inherent to using cell lines of different genetic backgrounds (discussed further below).
In spite of their self-renewal properties, human ES and iPS cells can still be difficult to genetically manipulate. Various techniques for stem cell genetic modification have been reported, and these can result in random (i.e., transgenic) or targeted integration of the DNA construct (reviewed in Giudice and Trounson, 2008) . Transgenic approaches include the use of plasmid transfection (Di Giorgio et al., 2008; Lakshmipathy et al., 2004; Siemen et al., 2005) , lentiviral transduction (Ben-Dor et al., 2006; Xia et al., 2007) , transposases (Lacoste et al., 2009; Wilber et al., 2007) , and bacterial artificial chromosomes (BAC) (Placantonakis et al., 2009) as DNA delivery systems.
Each of these strategies is in principal useful for the generation of both reporter systems and transgenic cell lines that either overexpress or suppress a given gene of interest. For instance, our group used plasmid transfection to generate a stable transgenic hES cell line that reports via GFP expression on spinal motor neuron differentiation (Di Giorgio et al., 2008) . Placantonakis and colleagues used BAC transgenesis of different reporter constructs to generate hES cell reporter lines that upon neural differentiation can report for neural stem cell, neuroblast, or motor neuron lineages (Placantonakis et al., 2009 ). In another study, Lacoste and colleagues engineered the piggyBac transposable system to deliver cocktails of doxycycline-inducible gain and loss-of-function transgenes into hES cells to efficiently direct their differentiation into neural rosettes (Lacoste et al., 2009) . Some of the limitations associated with transgenic approaches include the possibility of insertional mutagenesis, transgene silencing or ectopic expression of the transgene due to position effects, and lack of faithful expression of a reporter transgene due to absence of regulatory elements in the promoter fragment driving its expression (Giudice and Trounson, 2008) .
Unlike in mouse embryonic stem cells, where gene targeting by homologous recombination is routine, human pluripotent stem cells have proven to be more recalcitrant to this form of genetic modification. Thus far, only a few studies have reported the successful targeted genetic modification of human ES cell lines using conventional approaches (Costa et al., 2007; Davis et al., 2008; Di Domenico et al., 2008; Irion et al., 2007; Urbach et al., 2004; Zwaka and Thomson, 2003) . Recently, advances in the design of zinc finger nucleases (ZFNs) have shown promise for human ES and iPS cell-targeting experiments. Specific loci have now been disrupted, corrected, and modified to express reporter genes by means of a ZFN-mediated gene targeting (DeKelver et al., 2010; Hockemeyer et al., 2009; Lombardo et al., 2007; Zou et al., 2009) . ZFNs are engineered hybrid enzymes composed of DNA binding domains that bind to specific DNA sequences and a Fok1 nonspecific endonuclease domain (Klug, 2010) . These enzymes can be used to induce a double-strand break in a specific targeted location in the human genome, therefore allowing for increase likelihood of homologous recombination with an additionally provided exogenous DNA contruct (Klug, 2010) . The fidelity of this system relies on the specificity provided by the zinc finger DNA binding domains. Atlhough the selection and validation of ZFNs can be a costly or laborious process with significant lab expertise required (Doyon et al., 2008; Isalan et al., 2001; Maeder et al., 2008; Pearson, 2008) , the development of rapid, low-cost, and user-friendly in silico selection alternatives for designing functional ZFNs has recently been demonstrated (Sander et al., 2011) , which may improve the overall utility of ZFN techonology for gene-targeting experiments. In the context of hiPS cell disease modeling, the use of ZFN-mediated targeting to correct a genetic defect in a patient-specific iPS cell line and in turn rescue a disease-associated phenotype, remains to be demonstrated.
Given inherent genetic heterogenity between individuals, the issue of what constitutes the most appropriate control iPS cell line for any given patient-derived iPS cell line remains poorly defined. For single-gene defects, future use of gene-targeted approaches described above to generate isogenic control lines will undoubtedly be powerful tools. In addition, as several important neurological disorders are caused by gene defects on the X chromosome, iPS cell lines from females expressing either the mutant or normal allele based on which X chromosome has inactivated could theoretically provide useful phenotypic comparisons (see discussion on Rett Syndrome). However, for this approach to be successful, the dynamics of X chromosome inactivation in cultured human pluripotent stem cells needs to be more extensively studied. Apart from these approaches, the issue of what constitutes the best control line is currently unresolved. For monogenetic disorders, it will be necessary to show that the healthy controls do not harbor the disease-associated genotype. For example, use of cells from a healthy sibling who has tested negative for the disease-causing gene mutation, when available, would constitute a desirable control. For lateonset neurodegenerative disorders that are relatively common, the appropriate controls should be from individuals who are not only ''neurologically healthy'' but also advanced enough in age to minimize the possiblity of selecting a control that is at risk of developing the disease. In this regard, collaborations with neurologists and clinical follow-up of these patients will be important. Comparison of disease-specific iPS cell lines to well-characterized hES cell lines may be useful . Lastly, as it will be important to use several iPS cell lines from multiple patients the same will be true for control lines. Thus, the chances of phenotypic differences attributed to cellline-specific differences will be minimized. Will iPS Cell Models Be a Fruitful Approach for the Study of Adult-Onset, Sporadic Neurodegenerative Disease? Over the next several years, an expanding collection of diseasespecific iPS cell lines will be developed for both common and rare, monogeneic and idiopathic neurological diseases. While the above examples confirm that iPS cell model systems can, in certain cases, recapitulate disease-relevant phenotypes, it remains to be seen whether iPS cell lines can be informative for diseases with later-onset and polygenetic contributions.
Characterization of iPS cell models of monogenic forms of neurodegenerative diseases will be important test cases for disease modeling of more common sporadic forms, where multiple genes in interaction with poorly defined environmental risk factors contribute to disease. For example, in ALS, a neurodegenerative disorder of motor neurons leading to fatal paralysis with an average age of onset of 50 years and death within 3-5 years of onset, only 10% of cases are familial. Among the familial cases, mutations in SOD-1, TARDBP, and FUS account for a significant number of patients. iPS cell lines from patients with various mutations in SOD-1, the first identified and most extensively characterized ALS associated gene, have been generated and will be important resources to test whether motor neurons develop cellular pathologies that have been described in patient autopsy samples and transgenic mice . Any phenotypic changes found in familial ALS iPS-derived in vitro systems could then be tested in sporadic ALS iPS models.
While several groups have generated iPS cell lines from patients with other adult-onset, neurodegenerative disease such as AD, PD, and HD, reports of spontaneous phenotypic differences in differentiated cells from these disease-specific iPS lines has yet to emerge (Nguyen et al., 2011; Park et al., 2008a; Seibler et al., 2011; Soldner et al., 2009; Zhang et al., 2010) . For example, iPS cell lines, generated from fibroblasts forced to express pluripotency transcriptions factors using a doxycycline-inducible lentiviral vector that could be subsequently excised with Cre-recombinase, rendering these lines factor-free, were generated from patients with sporadic PD and directed to differentiate into dopaminergic neurons . Using a transplantation bioassay, implanted differentiated cells survived in the striatum of rats for at least 12 weeks with a small subset of cells expressing tyrosine hydroxylase and Girk-2 suggesting the presence of mesencephalic DA neurons. Similarly, cell injections of differentiated cells into the striatum of 6-hydroxydopamine (6-OHDA)-lesioned rats, a neurotoxic lesion model of PD, similarly survived and partially corrected amphetamine-induced rotational asymmetry suggesting a functional benefit . Interestingly, transplanted dopaminergic neurons from the PD-iPS did not contain inclusions of a-synuclein, a pathological hallmark of PD.
The lack of the formation of pathological aggregates in dopaminergic cells from sporadic PD-iPS cells gives some pause as to whether patient-derived iPS cells from a sporadic or lateonset disorder will show relevant phenotypes spontaneously in the time frame of in vitro experiments or in vivo assays. It is often argued that the time to produce disease in a patient correlates to the predicted length it may take to recapitulate disease phenotypes in culture. There is probably some truth to this assumption, as evidenced by the reported successes in iPS cell disease modeling in pediatric genetic diseases summarized previously. Development of methods to accurately correlate how a stem cell-derived neuron in culture correlates ontologically with the in vivo equivalent could be useful. However, neuronal dysfunction and degeneration as a result of the neurodegenerative process probably occurs much earlier than the initial neurological manifestations that characterize disease. For example, prior to the onset of the motor component of PD, a significant number of dopaminergic neurons have already been lost. Moreover, nonmotor manifestations can predate motor manifestations by years. In PD, one of the earliest symptoms of disease may be olfactory and autonomic dysfunction and initial a-synucleinpositive Lewy body pathology may occur in the dorsal motor nucleus of the glossopharyngeal and vagal nerves and anterior olfactory nucleus (Braak et al., 2003) . It would thus seem reasonable, in addition to studying midbrain dopaminergic neurons, whose degeneration causes the motor component of PD, to also consider developing directed differentiation methods from PD-iPS cells to obtain the cell types affected earliest in the disease.
Methods to accelerate the time to pathology in vitro will probably be important in adult-onset disease. Cellular stressors such as oxidative stress, growth factor withdrawal, starvation, selective neurotoxins, and heat shock may help reveal differences in iPS cell models. Taking this approach, dopaminergic neurons from iPS cell lines of an early-onset PD patient with a known mutation in LRRK2, demonstrated increased proportions of caspase-3 activation suggesting a selective vulnerability when exposed to a variety of cellular stressors including hydrogen peroxide, proteosome inhibition, and 6-OHDA exposure, though the differences were modest (Nguyen et al., 2011) . Differentiated neuronal cultures from PD-iPS cells expressed higher levels of a-synuclein, as compared to the neurons from control iPS and H9 ES cells, but whether this translated to pathological cytoplasmic aggregates was not discussed. Given that these results were based on lines generated from one patient and one healthy control, further work on additional patient and control lines is warranted. Regardless of these limitations, similar strategies are likely to be informative in iPS cell models of ALS, AD, and HD . In addition, developing iPS cell models from patients with particularly aggressive, early-onset forms of the disease may improve the likelihood of observing pathological phenotypes in culture.
In addition, with better methods to direct differentiation of pluripotent stem cells to nonneuronal cells, it may be possible to recapitulate the relevant microenvironments that provide the non-cell-autonomous factors that are important in several neurodegenerative diseases (Ilieva et al., 2009) . In this regard, ES cell-based coculture models have provided informative models of the non-cell-autonomous effects of glia in SOD-1-related ALS. For example, human ES cell-derived spinal motor neurons cultured in the presence of glial cells, either derived from SOD-1 transgenic mice or primary human astrocytes genetically modified to express mutant SOD-1, are selectively vulnerable to the toxic effects (Di Giorgio et al., 2008; Marchetto et al., 2008) . Furthermore, these culture models allowed for subsequent searches for candidate mechanisms by which mutant glia exerted their effects and testing of drugs to rescue motor neuron death. Thus, future iPS cell-based models composed of titrated populations of neurons, glia, and skeletal muscle to create a functional motor unit in vitro would be informative for studies of motor neuron disease. However, recapitulation of the full complexity of non-cell-autonomous mechanisms in vivo may be limited in vitro and thus correlation with established animal models would be important. Therefore, advances in tissue engineering, such as microfluidic or 3D platforms, to build more accurate spatial and temporal microenviroments for coculture approaches are likely to be exciting prospects for disease modeling (Kunze et al., 2011; Majumdar et al., 2011; Park et al., 2006; Taylor and Jeon, 2010) .
Lastly, while the modeling of genetically complex neurological disorders will be a difficult challenge, promising advances in an iPS cell model of schizophrenia (SCZD), a complex psychiatric disorder, gives evidence that this may be possible (Brennand et al., 2011) . Using a rabies transneuronal tracing approach, neurons generated from iPS cell lines of four patients with schizophrenia (SCZD-iPS) demonstrated decreased synaptic connectivity as compared to control-iPS cell-derived neurons, which was partially reversed by administration of the antipsychotic loxapine. However, decreased connectivity did not result in changes in synaptic function as assayed by electrophysiological and spontaneous calcium imaging methods. Interestingly, global analysis of gene expression changes comparing SCZDiPS-derived neurons to control revealed nearly 600 genes differentially expressed in SCZD neurons, 25% of which were previously implicated to SCZD (Brennand et al., 2011) . Comparison of these results to phenotypes from other SCZD-iPS lines, including rare genetically linked forms (Chiang et al., 2011) , will be important next steps to validate iPS cell-based modeling of genetically complex psychiatric disorders. Opportunity for Drug Screens for Efficacy and Preclinical Predictive Toxicology? Given the potential of human pluripotent stem cells and their differentiated cell types to model keys aspects of neurological disease, an obvious extension of this platform is in its use for drug discovery and predictive toxicology. As iPS cells can be generated from different patient populations, a diversity of drug responses and toxicity profiles could potentially be captured. High rates of attrition of new drugs are mostly attributed to failures in clinical efficacy or unforeseen toxicities and safety concerns, often occurring in later stages of clinical trials. Nearly 90% of new drugs tested in humans fail to ultimately come to clinical approval, with central nervous system disorders as a therapeutic area, among those with the highest rate of attrition (Kola and Landis, 2004) . Arguably, these failures have resulted from a reliance on imperfect models used during preclinical development. One could envision using human pluripotent cell-based assays in lead optimization for efficacy and also to identify, prior to first-in-human studies, drug toxicities.
As disease-specific stem cell models for neurological diseases continue to be validated, they are poised to become unprecedented tools for drug discovery using human cells (Ebert and Svendsen, 2010; Rubin, 2008) . However, before their full potential can be realized, several challenges must be overcome. It will be critical to identify robust assays that display diseaserelevant phenotypes and are readily amenable to large-scale drug screening. For example, high-throughput screening of compounds that improve motor neuron survival in SMA and ALS is one such achievable goal (Di Giorgio et al., 2008; Ebert et al., 2009; Rubin, 2008) . Thus, optimizing stem cell cultures and differentiation protocols for large-scale, automated, multiwell formats will be important technical goals.
Pluripotent stem cells may also find an important function in predicting whether lead compounds identified using the cells of a single patient will be equally effective in a large cohort of individuals. To this end, one could imagine convening a large set of iPS cell lines, which could then be arrayed in multiwell format. These ''arrayed'' stem cells would then be differentiated in parallel within the multiwell format into neurons that then could be exposed to the novel lead molecule. If the newly identified lead compounds worked well in disease models made from each of the genetically diverse cell lines within the array, then it could provide additional confidence that the compound in hand would function in a large number of patients. In turn if compounds are found to function in the neurons of some but not all stem cells within the array, the genetic signature of cells that respond best can be identified. This information would then be used to convene a clinical trial and administer the compound only to individuals with the response genotype. Such an approach could become a routine approach. First, one would screen many thousands of compounds using a disease-specific assay made from just one individual. Once a compound is discovered, its efficacy and the generality of its effectiveness would then be tested on neurons from the iPS cell lines of a large number of people. Such an approach could in principal lead to less expensive and more rapid clinical trials.
Human pluripotent cells could also be useful as a resource for studying predictive developmental toxicology (Laustriat et al., 2010) . A murine pluripotent stem cell-based assay (EST) evaluating the toxic effects of potential compounds on ES-derived cardiomyocytes has been validated (Genschow et al., 2002) . However, important species variation in predicting teratogenicity exist (Nau, 1986) . One notorious example in which animal testing failed to identify teratogenic effects in humans is the case of thalidomide, a drug prescribed to pregnant women between 1958 and 1961 for its antiemetic effects in treating morning sickness, which led to an epidemic of developmental abnormalities including limb deformities. Testing developmental neurotoxicities using human pluripotent stem cells has preliminary shown promise in modeling effects of nicotine (Zdravkovic et al., 2008) and methylmercury (Stummann et al., 2009) . Using metabolomic profiling of cultured human ES cells and neural precursor derivatives, it was shown that exposure to valproic acid, a widely used antiepileptic and known human teratogen, led to identifiable changes in the metabolomic profile, suggesting its use in identifying biomarkers of developmental toxicity (Cezar et al., 2007) . Furthermore, using metabolomic profiling of human ES cells exposed to a test set of drugs with or without known teratogenic effects, a specific metabolomic signature correctly predicted teratogenicity in 87% of the compounds (West et al., 2010) .
Given that cardiomyocytes and hepatocytes are clinically important cells types for drug toxicity studies, methods to direct the differentiation of human pluripotent stem cells along these lineages could be of tremendous value in predicting serious adverse effects leading to drug attrition and safety concerns (Dick et al., 2010) . Electrophysiological recordings of cardiomyocytes derived from human ES cells exposed to a test set of compounds accurately predicted their known affects on QT prolongation, a major risk factor for Torsade de Pointes and fatal ventricular arrhythmias (Braam et al., 2010) . One possible limitation is the relatively immaturity of cardiomyoctes but more mature cardiomyoctes have been obtained through better culturing methods (Otsuji et al., 2010) . Derivation of functional hepatocytes supporting CYP1A2 and CYP3A4 metabolism has also been successful, suggesting that iPS cell-derived hepatocytes may be useful in predicting differential metabolism and toxicity of drugs (Sullivan et al., 2010) .
Finally, we and many others are optimistic concerning the prospects of using iPS cells from patients with neurological syndromes to gain insight into their disease, as well as to discover potential therapeutics. However, it will be critical to keep in mind that iPS cells will be most powerfully leveraged as tools for biomedical research when they are used alongside existing animal, cell, and molecular models of neural degeneration.
Conclusions
If disease-specific iPS cells are to be translated into clinically informative models for mechanistic studies and therapeutic drug discovery, several basic requirements must ideally be met. First, it will be important to optimize methods for differentiating stem cells into the particular neural cell type of interest. In the specific case of the spinal motor neurons affected in ALS and SMA and midbrain dopaminergic neurons in PD, methods described in mouse and human embryonic stem cells have translated fairly well into iPS cells, though they are far from perfect. It may further be necessary to identify culture conditions to produce specific subclasses of the desired cell type. For example, in ALS, selective subclasses of motor neurons degenerate whereas other subclasses are preferentially spared (for example motor neurons of the oculomotor complex in the midbrain controlling eye movements and motor neurons of sacral spinal cord controlling bowel and bladder function). In PD, the A9 nigrostrial dopaminergic projection neurons are preferentially affected and are paramount for the motor symptoms that typify this disorder.
Second, phenotypic assays relevant to the disease process need to be established and advances in genetic modifications to create isogenic control lines will impart rigorous methods to compare disease versus control phenotypes. Needless to say, iPS cell models alone will not be able to produce clinically important read-outs of memory dysfunction and behavioral changes in AD or frontotemporal dementia, tremor, bradykinesia, and rigidity in PD, or reduced forced vital capacity, swallowing dysfunction, dysarthria, or limb motor impairment in ALS. However, recapitulation of key molecular, cellular, and anatomical changes involved in disease are well within the scope of disease-related phenotypes in culture. Expected phenotypes based on previously established animal and cellular models and observations from neuropathological studies should serve as a means to establish hypotheses or help validate the specific iPS model but the identification of novel mechanisms or cellular phenotypes remains an exciting possibility. Importantly, iPS cell models will allow for the study of human pathophysiology and pharmacologic responses.
Lastly, iPS cell-based models may provide a new opportunity to understand selective vulnerability of populations of neurons to discrete degenerative stimuli, a theme common to many neurological disorders. Thus, in coming closer to creating more relevant cellular models of human neurological disease, perhaps what we can create, we can understand.
